Volver al Panel







AstraZeneca PLC (AZN)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
AZN Intraday
No data available
SímboloAZN
Fecha de SalidaMay 12, 1993
CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.
Empleados a Tiempo Completo96.1k
SectorHealthcare
IndustriaDrug Manufacturers - General
PaísUnited Kingdom
BolsaNYSE
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | -0.56% | -0.99 US$ |
| 5 Días | -5.44% | -10.03 US$ |
| 1 Mes | +3.54% | +5.97 US$ |
| 6 Meses | -6.74% | -12.61 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de AZN...
Estadísticas Clave
Cap. de Mercado
270.40B
Relación P/E
24.66
Rend. de Div.
1.83%
Máx. 52 Semanas
$212.71
Mín. 52 Semanas
$153.41
Consenso de Analistas
CONSENSOCompra
ALCISTA975.0%
NEUTRAL216.7%
BAJISTA18.3%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$158.00
$158.00
Objetivo Máx.
$240.00
$240.00
Actual$174.42
Objetivo Prom.$209.91
Recomendaciones de Analistas
Precio Objetivo:$209.91($158.00 - $240.00)
¿Buscas más valores? Explóralos en el screener
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre AZN
Únase a la comunidad para compartir su análisis
Últimas Noticias para AZN
AstraZeneca leads European big pharma on growth, pipeline depth
Investing.com•20 nov 2026, 16:25

FDA Grants Priority Tag to AZN's BLA Filing for Gastric Cancer Drug
Zacks•20 nov 2026, 15:13


Big Pharma, with eye on Anthropic, says AI is shrinking drug discovery timelines
Reuters•20 nov 2026, 11:09
European shares tumble again as Anthropic debut fails to halt tech rout
Investing.com•20 nov 2026, 08:36

Why AstraZeneca Could Make Sense Through ETFs Now
Simply Wall St.•19 nov 2026, 16:09

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma Dive•19 nov 2026, 15:10


AstraZeneca Says FDA Grants Priority Review to Sonesitatug Vedotin for Gastric, GEJ Cancers
MT Newswires•19 nov 2026, 09:41